Ministry of Health study: Corona vaccine is 99% effective in preventing in preventing death

The Ministry of Health this evening released data showing that 14 days after receiving the second vaccine, the data are even higher than in Pfizer's initial study.
Corona vaccines in Israel have been found to be very effective in preventing illness, with an emphasis on serious illness, hospitalization and mortality - this evening (Saturday) increased the effectiveness of the vaccines performed by the Department of Epidemiology in the Ministry of Health. According to the results of the test, which was conducted until the previous weekend, there is an efficiency of 95.8% in preventing all cases of the disease from the virus.
The efficacy test measured the risk of developing the disease for people who were vaccinated with two doses of vaccine, compared to people who were not vaccinated at all. The vaccine has also been found to be 98% effective in preventing illness with fever or respiratory symptoms. 98.9% in the prevention of coronary heart disease, 99.2% in the prevention of severe coronary heart disease, 98.9% in the prevention of coronary heart disease.
According to the Ministry of Health, "vaccine benefit" measures the risk of contracting the disease for people who have been vaccinated with two doses of vaccine compared to people who have not been vaccinated at all. According to the latest data, the vaccine is found with very high benefit against morbidity, morbidity, hospitalizations and mortality.
The Director General of the Ministry of Health, Prof. Hezi Levy, said that "Thanks to the strong health care system of the State of Israel, which allowed us to reach a widespread vaccine in a short time in the population, and our ability for comprehensive epidemiological follow-up, we are the first country in the world to demonstrate the effect In a real clinical world. "
"The vaccine significantly reduces serious morbidity and mortality and this effect can be seen in the morbidity data in the country. Our goal is to continue to vaccinate the entire population from the age of 16 and up, and in time even under the age of 16, ".
This weekend, the first study of its kind was published in the professional journal "LANCET", which was conducted among 9,000 employees of Sheba Hospital in Tel Hashomer. A study showed that within two weeks of receiving the first dose of the corona vaccine, there was a 75% decrease in the rate of those infected with the virus among the vaccinated, and a 85% decrease in the rate of patients with corona symptoms.
The study was conducted among 9,000 employees of the medical center, of whom 7,214 received the first vaccine dose. Its purpose was to test the efficacy of the first dose of the vaccine only. In the study, workers were tested for four weeks after the first dose until the onset of the second dose - about a week after the second injection. The study examined how many vaccinated people were ill and how many of them developed symptoms of the disease.
Out of a total of 9,000 subjects, 170 contracted the virus during the weeks tested, with 99 of them also experiencing the symptoms of the disease to varying degrees. Of the patients who developed symptoms, 89 were not vaccinated and only ten were vaccinated against the virus.
The results of Sheba's research are consistent with, and even surpass, the results of Pfizer's clinical research, because during the study period Israel was under a particularly large wave of morbidity. The hospital reports that most of the staff members' illness came from the community, and not from infections within the walls of the place.

Newspapers and media networks around the world echoed yesterday (Monday) the results of Clalit HMO's huge study on the effectiveness of the Pfizer vaccine in preventing corona virus. According to the study, the effectiveness of the vaccine is 94%. The headline on the British BBC, which was the main article on the site, stated that "the vaccine has proven itself 'in real life' just like in the experiment". "The data demonstrate the efficacy of the vaccine on a large population just as it has been proven in the clinical trial," the BBC website said. "The pattern is the same in all age groups, including those aged 70 and over, even though they were only a small part of the experiments."
British Prime Minister Boris Johnson has also expressed interest in the data. The British Prime Minister said at a press conference yesterday that "Britain can not yet say exactly what the effect of the vaccine will be on the spread of the plague, but interesting information is coming to us from Israel." Johnson stressed that despite the good news about the effectiveness of the vaccine in the absence of accurate information about the UK "we must continue to be careful at the moment".
While the UK was the first in the West to start the vaccination campaign and now, according to Johnson, it is meeting the targets it has set for itself, in other European countries the vaccination campaign has not yet gained momentum due to mistakes and incorrect assessments by governments. According to CNN, the number of Britons who have so far received the first dose of the vaccine is higher than the number of vaccinated in Germany, France, Italy, Spain, Poland and Belgium combined. CNN added that the rate of vaccinators in the UK is the third highest in the world, after Israel and the United Arab Emirates.
 News of the success of the experiment also surfaced in the New York Post in the United States, on CNN, on CNBC and on the French FRANCE 24. "This approval is very important," said CNN health commentator Dr. Liana Wen.
"We have vaccinated more than 90% of those aged 70 and over in the country," Johnson said, "and this is an unprecedented moment in our national achievements, but it is not the moment to let go and rest. On the contrary, it is the moment to accelerate the operation because the threat from the virus remains real. "The operation is progressing well, we still do not have enough information about the effectiveness of the vaccine and reducing the spread of the virus. We have a basis to be sure of the effectiveness, but the operation only runs for a few weeks. Although we study all the time, we still do not have all the information we need."
According to a study by the Clalit Institute, which analyzed data from about 1.2 million insured members of the fund, including 600,000 vaccinated people who received the Pfizer vaccine, it was found that the vaccine has a high efficiency of 94% in preventing symptomatic infection and an efficiency of 92% in preventing serious illness. This is compared to 600,000 similar insureds who were not vaccinated.
Data from the Clalit Research Institute indicated high vaccine efficacy over a period of seven days or more after the second dose ("fully vaccinated"), adding information on preventing severe coronary heart disease. In fact, it can be said with high certainty that the effectiveness against a serious illness a week after the second dose ranges from 91% to 99%. With each passing week, the accuracy of the assessment will increase - and it is expected to continue to rise as more vaccines that have passed 14 days or more from the day they received the second dose are included.
"These results are the first swallow in a series of research results that complement the Clalit Research Institute for Evaluating Vaccine Efficacy in Various Groups and Outlines," said Prof. Ran Blitzer, director of the institute. "We had to face challenges related to the clear differences between the vaccinated and non-vaccinated populations and their change over time, as well as the effects of the closure imposed and removed during that period. Together with our Harvard colleagues we conducted a series of tests to validate the results, "The Pfizer vaccine is most effective in real life one week after the second dose, just as found in the clinical study."
Last week, the Maccabi HMO also published data on the effectiveness of the vaccine and stated that "less than 0.1% of the recipients of the second dose of the vaccine have contracted corona." According to the fund's data, 93% of the vaccine was effective. Most of those infected after the two doses of the vaccine had mild symptoms or no symptoms at all.